SCHEMBL30735877

SCHEMBL30735877

Cc1cc2c(nn1)NCCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
GRM5 P41594 2/20 0.41
FABP6 P51161 1/20 0.36
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
ATM Q13315 1/20 0.35
ADRA2A P08913 3/20 0.33
ADRA2C P18825 3/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1A P35348 3/20 0.33
ADRA1B P35368 3/20 0.33
ADRA2B P18089 2/20 0.33
ALOX5AP P20292 5/20 0.33
FEN1 P39748 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153298 0.73 ALDH1A1 (0.42) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL30657929 0.73 GRM5 (0.54) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL91447 0.73 GRM5 (0.54) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL27325551 0.72 NLRP3 (0.41) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL30960159 0.72 UHRF1 (0.49) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL2492111 0.70 GAA (0.47) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL13424834 0.70 ALDH1A1 (0.40) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL21605829 0.70 ALDH1A1 (0.40) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL5757962 0.69 GRM5 (0.40) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL4343282 0.69 ALDH1A1 (0.50) ALDH1A1GAAHSD17B10MAPTGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547663-A1 IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS F. Hoffmann-La Roche AG (CH) 2025-05-07 EP disclosed
US-20250115607-A1 PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-04-10 US disclosed
CN-119451959-A Imidazo [4,5-C ] pyridine derivatives as SIK modulators for the treatment of rheumatoid arthritis 豪夫迈·罗氏有限公司 2025-02-14 CN disclosed
WO-2024003209-A1 IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS F. HOFFMANN-LA ROCHE AG (CH) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115607-A1 PYRIDINE DERIVATIVES ADORA1, CYP1A1, MT-ND1 ALDH1A1 130/4885GAA 3070/4885HSD17B10 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.